Ablative Solutions closes $77m Series D

Ablative Solutions

Ablative Solutions said today that it closed a $77 million Series D funding round to help support its technology platform intended to treat hypertension.

The round was led by newly invested Gilde Healthcare and co-led by existing investor BioStar Ventures and an undisclosed new strategic corporate investor, the Kalamazoo, Mich.-based company said. Existing investors Michigan Accelerator Fund, Novus Biotechnology and other investors also joined the round, the company said.

Read the whole story on our sister site, Drug Delivery Business News

The post Ablative Solutions closes $77m Series D appeared first on MassDevice.